How the Most-Favored-Nation Pricing Policy Is Forcing Eli Lilly to Rethink Its European Weight-Loss Pill Launch

The Trump administration's Most-Favored-Nation (MFN) pricing policy, signed as an executive order on May 12, 2025, benchmarks U.S. drug prices to the lowest prices paid by other developed nations . The policy is now cascading through global pharmaceutical strategy — reshaping how Eli Lilly will launch its new weight-loss pill Foundayo (orforglipron) in Europe, depressing overall European drug launches, and compounding the effects of Germany's aggressive cost-cutting legislation on regional R&D investment and patient access.

Foundayo’s European Launch: A New Playbook

Eli Lilly expects to bring Foundayo to Europe and the UK in the second half of 2026 or early 2027 . The FDA approved the once-daily oral GLP-1 pill in the U.S. on April 1, 2026, under a National Priority Voucher program that completed review in a record 50 days . In clinical trials, patients on the highest dose lost an average of 11-12% of their body weight over 72 weeks .

The MFN policy is directly reshaping how the drug will reach European patients. Eli Lilly CEO David Ricks has stated that the company will still pursue public reimbursement from European governments, but the primary launch route will be via self-pay telehealth platforms — the same direct-to-consumer model used in the U.S. . This marks a fundamental shift: launching first into private cash-pay channels rather than waiting months or years for national reimbursement negotiations.

The mechanism is clear. On August 14, 2025, Eli Lilly raised the UK list price of Mounjaro (tirzepatide) by up to 170% — from £122 to £330 per month for the highest dose — explicitly as a response to Trump administration pressure to lower U.S. prices . By